Compound class:
Synthetic organic
Comment: Compound 13r is one of the analogues assessed in a study to identify selective inhibitors of bone morphogenetic protein receptor isotypes [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Compound 13r shows little selectivity across the members of the Type I receptor serine/threonine kinases family, which contains the bone morphogenetic protein receptors, and also inhibits transforming growth factor, beta receptor II (TGFBR2, a Type II receptor serine/threonine kinase) with IC50 of 15nM [1]. We have tagged ALK1/ACVRL1 as primary target for compound 13r based only on the fact that this is the first member of the protein family, with several members being equally sensitive to compound 13r inhibition. |
Selectivity at catalytic receptors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|